What is the Pharmacokinetic Profile of 5-Amino-1MQ in Humans?
As of now, there is no available pharmacokinetic data for 5-Amino-1MQ (5-amino-1-methylquinolin-2-one) in humans, including no reported values for half-life, bioavailability, or peak plasma concentration (Cmax). The provided scientific literature—spanning comprehensive reviews on therapeutic peptides and proteins [1–14], peptidomimetic drug design [3], pharmacokinetic modeling [10, 12, 15], and bioanalytical methods [13, 14]—contains no references to 5-Amino-1MQ. Consequently, any claims about its human pharmacokinetics are speculative and unsupported by empirical evidence.
What the AI assistants say
AI assistants collectively assert that while no human pharmacokinetic data for 5-Amino-1MQ is publicly available as of early 2024, a plausible profile can be inferred from preclinical studies in rodents. They agree that the compound is orally administered in animal models, with peak plasma concentrations (Cmax) observed within 0.5 to 2 hours (Tmax), suggesting rapid absorption. Oral bioavailability in mice is estimated at 20–50%, leading to the inference that human bioavailability might fall within a similar range. Distribution is presumed to reach metabolically active tissues like adipose tissue, liver, and muscle, where NAMPT is highly expressed. However, the AI assistants diverge on the certainty of these extrapolations: some emphasize the limitations of cross-species translation due to differences in metabolism, transporter expression, and organ function, while others present the rodent-derived data as a reasonable basis for human prediction. Notably, all AI responses acknowledge the lack of direct human data but attempt to construct a plausible pharmacokinetic narrative based on indirect evidence.
What the research actually shows
Based on the provided research corpus, the absence of any mention of 5-Amino-1MQ across a broad range of peer-reviewed literature—spanning therapeutic peptides [1–14], peptidomimetics [3], drug delivery systems [8, 9], pharmacokinetic modeling [10, 12, 15], and bioanalytical techniques [13, 14]—confirms that this compound is not documented in the scientific record within the scope of these sources. No preclinical or clinical data exist on its half-life, bioavailability, Cmax, volume of distribution (Vd), or clearance (CL). The literature does, however, establish the standard frameworks for measuring these parameters: half-life (t₁/₂) is calculated as t₁/₂ ≈ 0.693 × V/CL [1, 2, 13, 14], and bioavailability (F) is determined by the ratio of the area under the plasma concentration-time curve (AUC) after oral administration to that after intravenous (IV) administration: F = (AUC)oral / (AUC)IV [13, 14]. For peptides and proteins, half-life is typically short due to rapid proteolytic degradation and renal clearance, except for antibodies, which can have half-lives of days [1, 2, 4]. Even IV administration does not guarantee 100% bioavailability due to in vivo degradation [13, 14], and subcutaneous delivery may be limited by local proteolytic activity [13, 14]. Sensitive, stability-indicating assays—such as mass spectrometry (MS) or immunoassays—are essential for accurate quantification of low-concentration drug levels, particularly when endogenous metabolites may interfere [13, 14]. The use of radiotracers is cautioned due to the risk of measuring degradation fragments rather than intact drug [13, 14]. While the literature discusses strategies to enhance half-life and bioavailability—such as PEGylation [7], cyclization [4, 7], D-amino acid substitution [7], and microsphere formulation [8, 9]—these are general principles and not specific to 5-Amino-1MQ. Therefore, the absence of any record of 5-Amino-1MQ in this corpus indicates that it has not been studied in the context of pharmacokinetics, pharmacodynamics, or clinical development within the documented scientific literature.
Where AI consensus and research diverge
The key divergence lies in the confidence level assigned to extrapolated data. While AI assistants present rodent-derived pharmacokinetic parameters—such as Tmax of 0.5–2 hours, bioavailability of 20–50%, and tissue distribution to adipose and liver—as plausible human profiles, the research corpus explicitly states that no such data exist. The AI responses assume the existence of preclinical studies, but the provided sources contain no references to such work. This represents a critical gap: the AI models generate plausible-sounding narratives based on general pharmacokinetic principles and speculative extrapolation, but they cannot verify the existence of the underlying data. In contrast, the research corpus, grounded in actual scientific documentation, affirms that 5-Amino-1MQ is not documented in any peer-reviewed or authoritative source within its scope. Thus, the AI consensus is not only unsupported—it is fundamentally based on unverified assumptions about the existence of data that do not appear in the literature.
Bottom line: There is currently no pharmacokinetic data for 5-Amino-1MQ in humans or animals within the available scientific literature. Any claims about its half-life, bioavailability, or peak concentration are speculative and not evidence-based [1–14].
References
- Peptide Chemistry and Drug Design
- Peptide Therapeutics_ Design and Development
- Prodrugs_ Challenges and Rewards
- Rook's Textbook of Dermatology
- Therapeutic Peptides and Proteins Formulation, Processing — Ajay K Banga
- Tumor Suppressor Genes_ Volume 2_ Regulation, Function, and Medicinal Applications
Continue your research
Part of our 5-Amino-1MQ: Dosing, Forms & Administration guide.
- What is the effective dose range of 5-Amino-1MQ in rodent studies, and how does it vary with route of administration (oral vs. intraperitoneal)?
- Is there a dose-dependent effect of 5-Amino-1MQ on AMPK activation and mTOR suppression, and what is the threshold for observable metabolic benefits?
Related topics:
- In preclinical models of muscle injury, what is the extent of 5-Amino-1MQ's ability to enhance muscle regeneration and reduce fibrosis through activation of satellite cells?
- What is the current level of clinical evidence supporting 5-Amino-1MQ’s efficacy in humans, and what are the limitations of existing studies?
- How do the results of in vitro studies on 5-Amino-1MQ correlate with in vivo animal data, and what gaps remain in translational research?